about
Main roads to melanomaRegulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblastsPTEN function: how normal cells control it and tumour cells lose itTherapeutic Implications of Targeting AKT Signaling in MelanomamTOR complex 2 is required for the development of prostate cancer induced by Pten loss in miceRetroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo.Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injuryDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsTargeting mutants of PTEN reveal distinct subsets of tumour suppressor functionsTPIP: a novel phosphoinositide 3-phosphataseConcurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate CancerLoss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cellsActivation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.Prostate cancer induced by loss of Apc is restrained by TGFβ signalingPTEN knockdown alters dendritic spine/protrusion morphology, not densityInteractions between cells with distinct mutations in c-MYC and Pten in prostate cancer.Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomasThe role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysisImmunophenotype and molecular characterisation of adenocarcinoma of the small intestine.Basal epithelial stem cells are efficient targets for prostate cancer initiationInactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formationA detailed transcriptional map of the chromosome 12p12 tumour suppressor locus.Anti-tumor mechanisms of valproate: a novel role for an old drug.The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.Molecular pathways and targets in prostate cancerPTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells.Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanomaβ-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.Identification of patients at risk for hereditary colorectal cancerProtein tyrosine phosphatases as drug targets: PTP1B and beyond.A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cellsCell death proteins as markers of early postmortem interval.Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway.DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell linesmiR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancerPten Regulates Epithelial Cytodifferentiation during Prostate Development.Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.Genetic pathways to primary and secondary glioblastoma
P2860
Q21245465-9F0DC7AD-22CE-4157-84D7-9827C7826A1FQ24292424-B195C42F-7F5E-4BB3-83E5-5071ADC77EBFQ24528114-822913D1-DE9F-4BDE-A8AE-CC23B1E904BCQ24631438-FEBC920B-AA83-4581-8D62-0ED9F6709825Q24658113-B4082EC6-7A89-47E5-B039-3113F00585ABQ24794042-F93D1364-86E6-40B2-A775-959A8B8B67B4Q26828446-8351DDAD-9AC8-492B-82EC-D66C252CBA56Q27310171-3856C7CD-F97F-4180-9BA6-0F6322890D85Q28254233-9DB08154-F8D3-4973-8F57-4BB20CD9DCA2Q28343581-7CBC291A-38AA-461C-8028-9D0F9ADA8FC1Q28364566-010CAE18-1E94-4C7C-8A5B-51FC133F5C14Q28387281-D8D5D3EA-9ADE-43A1-B37C-1FC909A87824Q28388722-7B185C1F-7E60-4D03-AEDE-EF65942CD515Q30408632-DA650FAB-0297-4AC4-8842-63A7EBB7E35FQ30414232-651265CB-9B11-47DE-AC26-57E7EC5B36F6Q30415350-37CE0E9F-29D0-4982-B805-8BE6298F7971Q30866782-A70FDE8C-FB48-471F-9E01-471BE2F1AD6CQ33193334-2FDA8A7B-EE1B-41CE-A478-0BD3A4F031D9Q33577824-7ED1A8B2-7A3A-4E19-9977-96EDE2D7A08EQ33620113-8A89E879-5931-46C9-9253-255FBE47366CQ33664410-8BB49E87-4AA9-4861-9872-43009A7E419BQ33795723-4064E7B7-8305-4EA7-A1B9-B356B64C03ABQ34118721-274C74C0-8774-4D2B-9E50-DD5BC9C0DD9DQ34147644-7DBAA6EC-F6C8-48B3-8B44-737CD7549492Q34229795-70CE9051-BF53-4475-921E-AC76D19C3984Q34365632-22B85130-A9FE-4923-999A-B8AE97E3DC51Q34409067-9222FE04-3245-49A8-8CD0-17E8FAAD045BQ34420417-5B18E441-06BA-45C8-AC79-264117158F8DQ34539930-969A41A9-514C-48BB-9FC0-F419424F24DFQ34652530-AE9E3563-B5AB-42E6-B7A5-7690368594E2Q35020553-765DB298-A09C-47C9-90B8-3C39FD0A692DQ35045183-441F52A9-C49E-4F94-8A8C-E038C15B7FAAQ35057805-D1D3EE5B-5AA7-44D5-81D0-8E5D3CC78779Q35067955-EAE1B86D-B01F-4A3C-B426-64A81286F3C8Q35098017-2C27E200-D913-4E90-8169-610578C0933EQ35180831-E072B2AE-B139-4D5A-B600-734600071B0CQ35239611-AA09271C-37F2-4DF4-AC70-9CF21927830FQ35664021-EA3309F7-6977-4C7E-8C23-0EA6BB600321Q35720774-9E879F5B-3E93-42C7-8A96-FFF033982B36Q35757144-DD65FF63-4D77-4807-B3DD-9FE929550118
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
PTEN, a unique tumor suppressor gene.
@ast
PTEN, a unique tumor suppressor gene.
@en
type
label
PTEN, a unique tumor suppressor gene.
@ast
PTEN, a unique tumor suppressor gene.
@en
prefLabel
PTEN, a unique tumor suppressor gene.
@ast
PTEN, a unique tumor suppressor gene.
@en
P356
P1476
PTEN, a unique tumor suppressor gene.
@en
P2093
P304
P356
10.1677/ERC.0.0070115
P577
2000-06-01T00:00:00Z